

Product datasheet for TR304518

FGF13 Human shRNA Plasmid Kit (Locus ID 2258)

Product data:

Product Type: shRNA Plasmids

Product Name: FGF13 Human shRNA Plasmid Kit (Locus ID 2258)

Locus ID: 2258

Synonyms: DEE90; FGF-13; FGF2; FHF-2; FHF2; LINC00889

Vector: pRS (TR20003)

E. coli Selection: Ampicillin

Mammalian Cell Puromycin

Selection:

Format: Retroviral plasmids

Components: FGF13 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID =

2258). 5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.

RefSeq: <u>NM 001139498</u>, <u>NM 001139500</u>, <u>NM 001139501</u>, <u>NM 001139502</u>, <u>NM 004114</u>, <u>NM 033642</u>,

NM 004114.1, NM 004114.2, NM 004114.3, NM 033642.1, NM 033642.2, NM 001139498.1, NM 001139500.1, NM 001139501.1, NM 001139502.1, BC012347, BC012347.1, BC034340, NM 004114.5, NM 001139501.2, NM 001139502.2, NM 001139500.2, NM 033642.3,

NM 001139498.2

UniProt ID: Q92913

Summary: The protein encoded by this gene is a member of the fibroblast growth factor (FGF) family.

FGF family members possess broad mitogenic and cell survival activities, and are involved in

a variety of biological processes, including embryonic development, cell growth,

morphogenesis, tissue repair, tumor growth, and invasion. This gene is located in a region on chromosome X, which is associated with Borjeson-Forssman-Lehmann syndrome (BFLS), making it a possible candidate gene for familial cases of the BFLS, and for other syndromal and nonspecific forms of X-linked cognitive disability mapping to this region. Alternative splicing of this gene at the 5' end results in several transcript variants encoding different

isoforms with different N-termini. [provided by RefSeq, Nov 2008]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To


be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.



OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200

CN: techsupport@origene.cn

Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com





Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).